Malignant pleural effusion and algorithm management

Journal of Thoracic Disease

Volumn 5, Issue SUPPL.4, 2013, Pages

  Zarogoulidis, Konstantinos ^a   Zarogoulidis, Paul ^a,b   Darwiche, Kaid ^b   Tsakiridis, Kosmas ^c   Machairiotis, Nikolaos ^d   Kougioumtzi, Ioanna ^d   Courcoutsakis, Nikolaos ^e   Terzi, Eirini ^e   Zaric, Bojan ^f   Huang, Haidong ^g   Freitag, Lutz ^b   Spyratos, Dionysios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b RUHRLANDKLINIK   (Germany)

^c Saint Luke Private Hospital   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^f UNIVERSITY OF NOVI SAD   (Serbia)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Malignant pleural effusion (MPE); Pleurodesis; Suicide gene therapy; Thoracoscopy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; LACTATE DEHYDROGENASE; TALC; TETRACYCLINE;

ALGORITHM; CANCER PATIENT; CHEMICAL PLEURODESIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CYTODIAGNOSIS; DIAGNOSTIC IMAGING; HEALTH CARE POLICY; HUMAN; INDWELLING PLEURAL CATHETER; LUNG SHUNTING; MALIGNANT PLEURA EFFUSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PLEURAL CATHETER; PLEURECTOMY; PLEURODESIS; PLEUROPERITONEAL SHUNTING; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SUICIDE GENE THERAPY; THORACOCENTESIS; THORAX RADIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; VIDEO ASSISTED THORACOSCOPIC SURGERY;

EID: 84892406804     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.09.04     Document Type: Review

References (62)

1. Chernow B, Sahn SA. Carcinonomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977;63:695-702.
2. Sahn SA. Malignant pleural effusions. Semin Respir Crit Care Med 2001;22:607-16.
3. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
4. Noppen M. Normal volume and cellular contents of pleural fluid. Curr Opin Pulm Med 2001;7:180-2.
5. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 1995;170:69-74.
6. Antunes G, Neville E. Management of malignant pleural effusions. Thorax 2000;55:981-3.
7. Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985;56:905-9.
8. Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Vancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686-93.
9. Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13.
10. Assi Z, Caruso JL, Herndon J, et al. Cytologically proved malignant pleural effusions: distribution of transudates and exudates. Chest 1998;113:1302-4.
11. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985;60:158-64.
12. Woenckhaus M, Grepmeier U, Werner B, et al. Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology. J Mol Diagn 2005;7:517-24.
13. Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol 1991;4:320-4.
14. Ong KC, Indumathi V, Poh WT, et al. The diagnostic yield of pleural fluid cytology in malignant pleural effusions. Singapore Med J 2000;41:19-23.
15. Sallach SM, Sallach JA, Vasquez E, et al. Volume of pleural fluid required for diagnosis of pleural malignancy. Chest 2002;122:1913-7.
16. Benlloch S, Galbis-Caravajal JM, Martin C, et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006;107:1859-65.
17. Edmondstone WM. Investigation of pleural effusion: comparison between fibreoptic thoracoscopy, needle biopsy and cytology. Respir Med 1990;84:23-6.
18. Lee YC, Light RW. Management of malignant pleural effusions. Respirology 2004;9:148-56.
19. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003;58 Suppl 2:ii8-17.
20. Hung MS, Lin CK, Leu SW, et al. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J 2006;29:373-9.
21. Brock MV, Hooker CM, Yung R, et al. Can we improve the cytologic examinations of malignant pleural effusions using molecular analysis? Ann Thorac Surg 2005;80:1241-7.
22. Debeljak A, Kecelj P, Triller N, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflations for malignant pleural effusions. J BUON 2006;11:463-7.
23. Margaritora S, Cesario A, Vita ML, et al. Single versus, multiple access video-assisted thoracic surgery in the treatment of malignant pleural effusion. Eur J Cardiothorac Surg 2007;32:397; author reply 397-8.
24. Stefani A, Natali P, Casali C, et al. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.Eur J Cardiothorac Surg 2006;30:827-32.
25. Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management of malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006;29:829-38.
26. Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003;58 Suppl 2:ii29-38.
27. Emad A, Rezaian GR. Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. A comparison of bleomycin or tetracycline alone versus a combination of bleomycin and tetracycline. Cancer 1996;78:2498-501.
28. Freitas S, Jones J, Cordeiro C, et al. Pleurodesis with tetracycline or with talc-Variables in terms of effectiveness. Rev Port Pneumol 2005;11:13-4.
29. Martínez-Moragón E, Aparicio J, Rogado MC, et al. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 1997;10:2380-3.
30. Villanueva AG, Gray AW Jr, Shahian DM, et al. Efficacy of short-term versus long-term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994;49:23-5.
31. Haddad FJ, Younes RN, Gross JL, et al. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg 2004;28:749-53; discussion 753-4.
32. Kilic D, Akay H, Kavukcu S, et al. Management of recurrent malignant pleural effusion with chemical pleurodesis. Surg Today 2005;35:634-8.
33. Ong KC, Indumathi V, Raghuram J, et al. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology 2000;5:99-103.
34. Patz EF Jr, McAdams HP, Erasmus JJ, et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998;113:1305-11.
35. Sartori S, Tassinari D, Ceccotti P, et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol 2004;22:1228-33.
36. Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. World J Surg Oncol 2004;2:16.
37. Barbetakis N, Vassiliadis M, Kaplanis K, et al. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. BMC Palliat Care 2004;3:4.
38. Schmidt M, Schaarschmidt G, ChemaissaniA. Pleurodesis in malignant pleural effusion: bleomycin vs mitoxantrone. Pneumologie 1997;51:367-72.
39. Heffner JE, Klein JS. Recent advances in the diagnosis and treatment of malignant pleural effusions. Mayo Clin Proc 2008;83:235-50.
40. Dasmahapatra KS, Citrin P, Hill GJ, et al. A prospective evaluation of 5-fluoroucasil plus cisplatin in advanced squamous-cell cancer of the head and neck. J Clin Oncol 1985;3:1486-9.
41. Seto T, Ushijima S, Yamamoto H, et al. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 2006;95:717-21.
42. Shoji T, Tanaka F, Yanagihara K, et al. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest 2002;121:821-4.
43. Hoffer FA, Hancock ML, Hinds PS, et al. Pleurodesis for effusions in pediatric oncology patients at end of life. Pediatr Radiol 2007;37:269-73.
44. Kuzdzał J, Sladek K, Wasowski D, et al. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective randomized trial. Med Sci Monit 2003;9:P154-9.
45. Porcel JM, Salud A, Nabal A, et al. Rapid pleurodesis with doxycycline through a amll-bore catheter for the treatment of metastatic malignant pleural effusions. Support Care Cancer 2006;14:475-8.
46. Ohta Y, Shimizu Y, Matsumoto I, et al. Management of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis. J Exp Clin Cancer Res 2006;25:15-9.
47. Perng RP, Chen YM, Wu MF, et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med 1998;92:473-9.
48. Balassoulis G, Sichletidis L, Spyratos D, et al. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol 2008;31:384-9.
49. Miller Q, Meschter C, Neumaster T, et al. Comparison of pleurodesis by erythromycin, talc, doxycycline and diazepam in a rapid model. J Surg Educ 2007;64:41-5.
50. Tang X, Cheng D. The value of erythromycin pleurodesis in the treatment of malignant pleural effusions. Hua Xi Yi Ke Da Xue Xue Bao 1997;28:437-9.
51. Foresti V. Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions. Respiration 1995;62:21-6.
52. Olivares-Torres CA, Laniado-Laborin R, Chavez-Garcia C, et al. Iodopovidone pleurodesis for recurrent pleural effusions. Chest 2002;122:581-3.
53. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007;369:1535-9.
54. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J 2001;18:402-19.
55. Antony VB, Rothfuss KJ, Godbey SW, et al. Mechanism of tetracyclinehydrochloride-induced pleurodesis. Am Rev Respir Dis 1992;146:1009-13.
56. Belani C, Ziskind A, Dhawan M, et al. Management of malignant pleural and pericardial effusions. Comprehensive Textbook of Thoracic Oncology, Williams and Wilkins, 1996;43:880-905.
57. Owen S, Gould D. Underwater seal chest drains: the patient's experience. J Clin Nurs 1997;6:215-25.
58. Clementsen P, Evald T, Grode G, et al. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir Med 1998;92:593-6.
59. Goff BA, Mueller PR, Muntz HG, et al. Small chest-tube drainage followed by bleomycin sclerosis for malignant pleural effusions. Obstet Gynecol 1993;81:993-6.
60. Chen YM, Shih JF, Yang KY, et al. Usefulness of pig-tail catheter for palliative drainage of malignant pleural effusions in cancer patients. Support Care Cancer 2000;8:423-6.
61. Genc O, Petrou M, Ladas G, et al. The long-term morbidity ofpleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000;18:143-6.
62. Zarogoulidis P, Chatzaki E, Hohenforst-Schmidt W, et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. Cancer Gene Ther 2012;19:593-600.